Ann Janssens, MD

Department of Hematology Campus Gasthuisberg, University Hospital, Leuven, Belgium, Belgium

N/A

Poster(s):

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial

• 1606 - Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial